UCB on track for solid year as Vimpat heads for blockbuster status

30 October 2018

UCB (Euronext: UCB) has sustained its stable rate of growth and remains on target to meet its 2018 expectations, according to its results from the first nine months of the year.

Revenue for the nine months was 3.4 billion euros ($3.9 billion), a 3% rise on the same period of 2017, with sales of UCB’s five main products up 6% at 2.8 billion euros.

The Belgian drugmaker, which specializes in neurology and immunology, has confirmed its financial outlook for 2018, predicting that revenue for the year will be between 4.5 billion and 4.6 billion euros. Core earnings are expected to be in the range of 4.30 to 4.70 euros.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK